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A CASE OF HASHIMOTO’S ENCEPHALOPATHY IN A PATIENT WITH SUSPECTED LITHIUM TOXICITY
ABSTRACT
Hashimoto’s encephalopathy is a rare neurological disorder of unknown etiology. We presented, a case of middle aged
male with bipolar disorder on Lithium carbonate for 30 years, admitted with altered behavior for 2 weeks and high
Lithium levels. He was admitted with the suspicion of Lithium toxicity. EEG showed generalized epileptiform discharges.
MRI brain revealed frontal cortical atrophy. CSF detailed report was normal. Further workup showed a high TSH level
and positive anti-TPO (anti thyroid peroxidase) antibodies. Based on clinical picture, raised antibodies and no
discernible cause, diagnosis of probable Hashimoto’s encephalopathy was made. He received pulse of
methylprednisolone for five days and his symptoms improved dramatically. Our case report highlights the importance
of diagnosing a rare neurological syndrome in a complex clinical scenario.
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INTRODUCTION:

days and was found unresponsive outside shopping
mall. During these two weeks patient has been
unpredictable, shouting obscenities, responding to
internal stimuli and smiling. He developed tremors in
both hands 6 months back and there was a history of
stimulant use in the past. He was being treated for
bipolar disorder with Lithium 300mg thrice daily and
Carbamazepine 200 mg twice daily for the past 30
years and was on Lisinopril 5 mg daily for hypertension.
Before illness he usually have mood swings but able to
perform his work well. On examination, he was a
middle-aged male, lying on bed, conscious, aggressive,
not following commands and with significant palilalia.
Neurological examination showed grossly intact cranial
nerves, increased tone in all four limbs, no focal deficit,
normal reflexes and downgoing plantars .No signs of
meningeal irritation, nystagmus or myoclonus. Baseline
workup revealed Hemoglobin of 9.6 gm/dl (Normocytic
normochromic) deranged renal parameters (urea:150
mg/dl,Creatinine:3.44 mg/dl) , TSH of 6 Miu/L(0.4-4)
Lithium levels of 3.9 mmol/L (0.4-2 mmol/L ) His
lithium was stopped and intravenous hydration was
started. EEG showed generalized epileptiform

Hashimoto’s encephalopathy (HE) is an uncommon
neurological syndrome associated with Hashimoto’s
thyroiditis, first reported by Brain et al in 1966.(1) The
disease includes a wide spectrum of neurologic
symptoms ranging from stroke like presentation to
diffuse progressive pattern of slow cognitive decline
with dementia, confusion and hallucination.Treatment
with corticosteroids is almost always successful. Other
forms of immunomodulation, such as intravenous
immune-globulin and plasma exchange, may also be
effective.
CASE REPORT:
A 55 years old businessman, known case of
Hypertension and Bipolar disorder for 30 years was
admitted through outpatient department with irrelevant
talking for 2 weeks. His family was concerned for the
recent changes in the patient’s behaviour as he was
not recognizing, passing stool in the bedroom,
extremely irritable and agitated. He also left home for 2
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without
neuropsychiatric
symptoms;
seizures;
stroke-like events; focal neurological deficit or
movement disorders; elevated antithyroid antibodies;
and corticosteroid responsiveness.4

discharges. MRI brain showed frontal cortical atrophy,
without any contrast enhancement. CSF detailed report
was unremarkable. HIV and VDRL serologies were
negative. Patient was started on Acyclovir and Sodium
valproate due to the presence of epileptiform
discharges. Carbamazepine was continued. He
received Haloperidol and later, kept on Queitiapine (25
mg twice a day) for agitation. During the seven days of
hospital stay despite of correction of metabolic
parameters patient did not show any improvement.
HSV PCR came out as negative. His workup (anti
NMDA antibodies, anti GABA antibodies) for
autoimmune encephalitis was negative. Anti TPO
(anti-thyroid peroxidase) came out to be positive and
patient was given pulse of methylprednisolone for 5
days. His symptoms improved dramatically and he was
discharged after 7 days, on tapering doses of steroids.

EEG abnormalities are seen in 90% to 98% of patients
with HE, usually a nonspecific slow background activity.
Focal spikes or sharp waves and transient epileptic
activity are less common5
EEG performed on two occasions in our patient showed
generalized epileptiform discharges.
In a review of 82 patients with HE, brain computed
tomography or MRI showed abnormalities in 49% such
as cerebral atrophy, focal cortical abnormality, diffuse
subcortical abnormality and nonspecific subcortical
focal white matter abnormality6. Our patient showed
frontal cortical atrophy with no parenchymal
abnormalities, which is either due to bipolar disorder or
a part of Hashimoto’s encephalopathy.

DISCUSSION:
Hashimoto’s encephalopathy (HE) is an uncommon
neurologic syndrome associated with Hashimoto’s
thyroiditis, first reported by Brain et al in 1966. He
reported an individual with autoimmune thyroid disease
who presented with recurrent stroke-like episodes
occurring independently of the thyroid status.1,2

Elevated titers of antithyroid antibodies (especially
TPO-Ab) are the most relevant paraclinical finding,
which could be considered to be a hallmark of
HE.Presented case showed, that all patients with
progressive cognitive impairment or with a dementia of
unclear origin should be tested for HE.

The etiology of HE remains unclear. The mechanism of
HE does not appear to be related to the thyroid status
and varies from patient to patient. In two recent
reviews, 23% to 35% of patients had subclinical
hypothyroidism, 17% to 20% had hypothyroidism, 7%
had hyperthyroidism and 18% to 45% were euthyroid.4
Our reported case was hypothyroid. The development of
neurological symptoms may occur

The diagnosis of HE should be considered even if
Hashimoto's thyroiditis is not known in patients with
euthyroid states but with high serum and/or CSF titers
of antithyroid antibodies. About 50% of cases are
non-responders to corticosteroid therapy, thus
non-responsiveness should not be exclusion criteria for
HE, other therapeutic strategies should be tried:
immunosuppressive
therapy
(azathioprine
or
cyclophosphamide) and recently proposed in some
cases plasmapharesis or intravenous immunoglobulins.
Our patient responded well to corticosteroid pulse
therapy.7,8

A
hospital
based
epidemiologic
study
on
symptomatology consistent with HE showed prevalence
to be about 2.1 per 100,000.3 The disorder occurs
more frequently between age 44 to 46 years, with a
female-to-male ratio of four to one, consistent with our
patient.
Literature reviews suggests two major patterns of
presentation about 25% of patients followed a
stroke-like pattern of multiple recurrent episodes of
focal neurologic deficits with a variable degree of
cognitive dysfunction and consciousness impairment,
remaining 75% present with a diffuse progressive
pattern of slow cognitive decline with dementia,
confusion and hallucinations.3

Our patient was admitted with the suspicion of Lithium
toxicity due to high serum lithium levels. Laboratory
workup revealed high urea. His mental status did not
improve despite the correction of deranged metabolic
parameters. We exclude all other infective causes of
encephalopathy by MRI brain and CSF studies. This led
us to think of atypical causes of encephalopathy like
NMDA encephalitis and Hashimoto’s encephalopathy.
Positive anti thyroid peroxidase antibodies and dramatic
response to steroids prove it to be a case of
Hashimoto’s encephalopathy.

Shaw et al proposed the diagnostic criteria for HE
based on the presence of cognitive impairment with or
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T2 Weighted image showed significant frontal cortical
atrophy .

Conflict of interest: Author declares no conflict of interest.
Funding disclosure: Nil
Author’s contribution:
Saba Zaidi: Study concept and design, data collection, data analysis, manuscript writing, manuscript review
Bashir A. Soomro: data analysis, manuscript writing, manuscript review

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

37

VOL. 12 (1) JAN

-

MAR

2017

